

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Stancic Ana</u> <hr/> (Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC. 20 KINGSBRIDGE ROAD <hr/> (Street) PISCATAWAY NJ 08854 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ENZON PHARMACEUTICALS INC [ENZN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) <u>Executive VP, COO, PEO, CFO</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/17/2012</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common Stock ⁽¹⁾	01/17/2012		D ⁽²⁾		45,000	D	\$0	15,000	D		
Common Stock ⁽¹⁾	01/17/2012		A ⁽²⁾		45,000	A	\$0	70,000	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

- Restricted Stock Units ("RSUs") granted by the Issuer pursuant to its 2011 Stock Option and Incentive Plan and qualified under Rule 16b-3(d). Each unit represents a contingent right to receive one share of the Issuer's Common Stock.
- The two reported transactions involved an amendment of an outstanding RSU grant, resulting in the deemed cancellation of the "old" RSUs and the making of a replacement RSU grant. The RSU grant was originally made on November 17, 2011, and provided that the RSUs would vest in full on November 17, 2014, if the Reporting Person remained employed by the Issuer on such date; provided, however, that the vesting of 50% of the RSUs was to be accelerated upon the Reporting Person's achievement of certain performance milestones determined by the Board of Directors of the Issuer. On January 17, 2012, the RSU grant was amended to provide that the RSUs will vest in three (3) tranches. Of the 45,000 RSUs granted, 15,000 RSUs will vest on each of November 17, 2012, November 17, 2013 and November 17, 2014, in each case if the Reporting Person remains employed by the Issuer on such date.

/s/ Andrew Rackear, Attorney-in-Fact 01/19/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.